Search Results
Your search for Hope matches 3227 pages
Showing 2001 - 2050Maintaining Predictable Increases in NIH Funding for Cancer Research
CONGRESS RECENTLY passed its fiscal year (FY) 2017 spending bill, which contains an additional $2 billion for the National Institutes of Health (NIH). This marks the first time in more than a dozen years that Congress funded back-to-back increases for the NIH, demonstrating the bipartisan...
Educating Young People on Sun-Safe Behaviors and Reducing the Risk of Melanoma
“If minors don’t tan, then they may never become adult tanners,” Jeffrey E. Gershenwald, MD, said in explaining the emphasis on teaching sun safety behaviors to young children as part of the Melanoma Moon Shot Program at The University of Texas MD Anderson Cancer Center, Houston. Dr. Gershenwald is ...
Stereotactic Body Radiotherapy for Poor Performance Status Patients With Pancreatic Cancer
There are few data to guide the management of nonmetastatic pancreatic ductal adenocarcinoma in patients who are elderly or have a poor performance status. Although most such patients are offered supportive care or gemcitabine alone, the addition of stereotactic body radiotherapy may improve...
Advance Care Planning: Ensuring Patients’ End-of-Life Wishes Are Honored
When Amy Berman, BSN, LHD (aged 58), stood in front of the mirror to perform a routine breast self-exam and saw redness and dimpling on her right breast, she feared they were the telltale signs of inflammatory breast cancer. “I have never self-diagnosed myself before, but I had recently read an...
Appropriate Distress Screening and Follow-up Leads to Fewer ER Visits and Hospitalizations in Patients With Cancer
Following a cancer diagnosis, all patients experience some level of distress—regardless of disease stage. When severe and left untreated, distress can have a significant impact on health outcomes, lead to greater mortality and morbidity, affect immune function, and result in higher...
Blinatumomab Granted Full Approval to Treat Relapsed or Refractory B-cell Precursor ALL in Adults and Children
On July 11, the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA) for blinatumomab (Blincyto) to include overall survival data from the phase III TOWER study. The approval converts blinatumomab's accelerated approval to a full approval. The sBLA...
Pembrolizumab Is Highly Active in Relapsed/Refractory Classical Hodgkin Lymphoma
AS REPORTED in the Journal of Clinical Oncology by Robert Chen, MD, of City of Hope National Medical Center, and colleagues, the phase II KEYNOTE-087 trial has shown that the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab (Keytruda) is highly active in patients with relapsed/...
Second Cancers May Be Deadlier in Child, Adolescent, and Young Adult Patients
Second cancers in children and adolescents and young adults (AYAs) are far deadlier than they are in older adults and may partially account for the relatively poor outcomes of cancer patients between the ages of 15 and 39 overall, a new study by researchers at the University of California, Davis...
James Francis McCarthy
The family and staff of Harborside Press mourn the loss of former colleague, and forever friend James F. McCarthy, who passed away after a brief illness on June 23, 2017. Born in Brooklyn, New York, on January 7, 1929, to John A. and Eda K. McCarthy, Jim was a graduate of Brooklyn Preparatory High ...
Expert Point of View: Hans Hammers, MD, PhD
THE COMBINATION of checkpoint inhibitors and vascular endothelial growth factor (VEGF) inhibitors is attractive in renal cell carcinoma, said formal discussant of this trial, Hans Hammers, MD, PhD, of the University of Texas Southwestern Medical Center in Dallas. “Twenty-one percent of patients...
Big Data and the Learning Machine
BOOKMARK Title: The Master Algorithm: How the Quest for the Ultimate Learning Machine Will Remake Our WorldAuthor: Pedro DomingosPublisher: Beacon PressPublication date: February 2017Price: $24.95, hardcover, 288 pages Technology is revolutionizing our understanding and treatment of diseases....
Fat Grafting and Patient-Reported Outcomes in Postmastectomy Breast Reconstruction
The use of fat grafting as a tool for breast reconstruction following a mastectomy may improve breast satisfaction, psychosocial well-being, and sexual well-being in patients, according to a study published by Bennett et al in JAMA Surgery. Fat grafting as an adjunct to breast reconstruction...
CAR T-Cell Therapy in Multiple Myeloma Yields 100% Response Rate
Chinese investigators reported that 100% of patients with relapsed or refractory multiple myeloma responded to autologous chimeric antigen receptor (CAR) T-cell therapy, and 14 of 19 (74%) who were followed for a median of 4 months achieved a stringent complete response and have not recurred.1...
New Supportive Care Resources From NCCN Help Patients With Cancer Confront Distress
All patients with cancer experience some level of distress associated with their cancer diagnosis and the effects of the disease and its treatment—regardless of the stage of disease. Not only does distress affect a patient’s mental and psychosocial well-being, but because distress is a risk...
The Emperor’s New Clothes: Biosimilars and Cost in Oncology
Biosimilars are biologic products similar to the parent (branded) molecule in structure and function—such as erythropoietin and filgrastim (Neupogen).1 To truly bend the cost curve, we want to see a dramatic economic savings achieved as oncology biosimilars for rituximab (Rituxan), trastuzumab...
Pembrolizumab Moving Forward in Triple-Negative Breast Cancer
In the treatment of triple-negative breast cancer, checkpoint inhibition is making inroads in both early- and late-stage disease, and the line of treatment and expression of the programmed cell death ligand 1 (PD-L1) could be important in determining outcomes, according to studies reported at the...
First Comprehensive Pediatric Hematology/Oncology Initiative Launched in Africa
Through public-private partnerships with the governments of Botswana, Uganda, and Malawi, His Excellency the President Lieutenant General Dr. Seretse Khama Ian Khama, of the Republic of Botswana; the Honorable Minister Dorcas Makgato, of the Ministry of Health and Wellness; the Bristol-Myers Squibb ...
FDA Approves Panitumumab for Use in Wild-Type RAS Metastatic Colorectal Cancer
On June 30, 2017, the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA) for panitumumab (Vectibix) for patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic...
Scalp Cooling to Prevent Chemotherapy-Induced Alopecia: Is It Now Ready for Prime Time?
In oncology, sometimes we forget about the small, everyday things that can significantly impact a patient’s life. When patients are explained the side effects of chemotherapy and chemotherapy-induced alopecia, most women will cry or become visibly upset. When a woman loses her hair, it represents...
Two Studies Show Scalp Cooling Reduces Hair Loss in Women Receiving Chemotherapy for Breast Cancer
An interim analysis of the SCALP trial, reported in JAMA by Julie Nangia, MD, of Baylor College of Medicine, and colleagues, showed that use of a scalp-cooling device significantly reduced hair loss in women receiving chemotherapy for stage I or II breast cancer compared with no scalp cooling.1 The ...
FDA Approves Panitumumab for Use in Wild-Type RAS Metastatic Colorectal Cancer
Today, the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA) for panitumumab (Vectibix) for patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer...
Promoting Physician Wellness: An Overview of ASCO Initiatives
Suresh S. Ramalingam, MD Professor of Hematology and Medical Oncology, Director of Medical Oncology, Assistant Dean for Cancer Research, Emory University School of Medicine; Roberto C. Goizueta Distinguished Chair in Cancer Research, Deputy Director, Winship Cancer Institute ASCO Member since ...
Expert Point of View: Harold Burstein, MD, Carey Anders, MD, and William Sikov, MD
Several breast cancer experts weighed in on the findings of the APHINITY trial. At an ASCO press briefing, Harold Burstein, MD, Associate Professor of Medicine at Harvard Medical School and breast cancer specialist at Dana-Farber Cancer Institute, Boston, pointed out that investigators estimated a ...
Strides Being Made in Advanced Urothelial Cancer
According to Srikala S. Sridhar, MD, MSc, FRCPC, of the Princess Margaret Cancer Centre, Toronto, Canada, “It’s an exciting time in the field of urothelial cancer,” thanks to the emergence of new therapies such as the immune checkpoint inhibitors and other approaches that aim to improve both...
Identifying Genetic Basis for Extraordinary Clinical Responses May Accelerate Development of New Therapies
Accelerating the discovery of targeted cancer therapies requires defining the targets present in individual tumors, and there are two main ways to do this, David B. Solit, MD, told participants at the inaugural OncoSET Symposium: Emerging Approaches to Precision Medicine in Chicago.1 The...
ASCO Applauds NIH Director Francis Collins, MD, PhD, for Remaining in Critical Leadership Position
ASCO President Bruce E. Johnson, MD, FASCO, released the following statement on June 8: ASCO congratulates Francis S. Collins, MD, PhD, on the announcement of his continued service as the Director of the National Institutes of Health (NIH). A renowned researcher and skilled administrator, Dr....
Expert Point of View: Sumanta Kumar Pal, MD and John V. Heymach, MD, PhD
ASCO spokespersons at the press briefing lauded the results with larotrectinib and called for broader testing for tropomyosin receptor kinase fusions. The data for larotrectinib “bring us into a new era where treatment is truly based on mutation, not location,” said Sumanta Kumar Pal, MD, a...
Expert Point of View: Sumanta Pal, MD
LATITUDE Trial ASCO expert Sumanta Pal, MD, of the City of Hope Comprehensive Cancer Center in Duarte, California, commented on the LATITUDE trial at a press conference. “In 2014, docetaxel added to hormonal therapy showed an improved survival benefit in two trials—CHAARTED and STAMPEDE. It was no ...
NCCN Guidelines® Compliance for Chest CT May Reduce False Positives and Decrease Health-Care Spending in Breast Cancer
According to Surveillance, Epidemiology, and End Results (SEER) data, more than 260,000 women were diagnosed with breast cancer in the United States in 2016, most of whom were diagnosed with early-stage (stage I or II) disease. For this demographic, the National Comprehensive Cancer Network®...
USPSTF Emphasizes Importance of Informed Discussions About PSA Screening for Men Aged 55 to 69 Years
For a man aged 55 to 69 years, the decision to be screened for prostate cancer should be an individual one, based on the man’s own values and priorities and discussions with a clinician about the potential benefits and harms of screening, the U.S. Preventive Services Task Force (USPSTF) advised in ...
Seattle Children’s Clinical Trial on Molecular Diagnostics Opens for Pediatric Patients
IN AN EFFORT to find new strategies to personalize treatment for pediatric patients, Seattle Children’s Hospital has opened the first clinical trial applying next-generation T-cell receptor (TCR) sequencing and single-cell gene expression analysis to better understand how the immune system drives...
Learn How to Implement a Biopsychosocial Screening Training Program
A NATIONAL CANCER INSTITUTE (NCI)-funded training program in distress screening is being offered at no cost for competitively selected trainees in September 2017 at City of Hope, Duarte, California. Oncologists and other health-care professionals who are interested in learning how to successfully...
Brief Psychological Interventions Positively Affect Cancer Patients’ Well-Being
Three separate brief psychological interventions aimed at helping cancer patients cope with distress have shown improvements in quality of life and well-being across the continuum of cancer care. The interventions were studied—respectively—in newly diagnosed cancer patients, survivors after cancer...
ICML 2017: Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma
An updated interim analysis from an ongoing phase I/II clinical trial evaluating brentuximab vedotin (Adcetris) and nivolumab (Opdivo) in relapsed or refractory classical Hodgkin lymphoma was presented at the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland (Abstract...
AACR Publishes First Set of Screening Recommendations Emerging From Childhood Cancer Predisposition Workshop
The American Association for Cancer Research (AACR) has published its first set of consensus screening recommendations for children with common cancer predisposition syndromes in Clinical Cancer Research. These recommendations emerged from the Childhood Cancer Predisposition Workshop held by the...
Leave a Legacy of Hope
By including a planned gift to the Conquer Cancer Foundation in your estate plans, you can help make a dramatic difference for cancer patients years—even decades—into the future. With just one small change to your will or trust, your planned gift of any size will deliver a big impact, and: Your...
Targeting the Androgen Receptor in Breast Cancer
One of the most active areas of research in breast cancer involves the targeting of the androgen receptor. Trials underway for androgen receptor antagonists and modulators, alone and in various combinations of available agents and novel therapies, are yielding encouraging early results. At the 2017 ...
Idelalisib Toxicities Appear to Be Immune-Related
Phosphoinositide 3-kinase (PI3K) inhibitors represent a highly active class of drug for the treatment of chronic lymphocytic leukemia (CLL). Idelalisib (Zydelig), a PI3K-delta inhibitor and the first PI3K inhibitor to be approved by the U.S. Food and Drug Administration (FDA) for CLL, has...
ASCO 2017: I-SPY 2 Trial: Combination of Pembrolizumab Plus Standard Neoadjuvant Therapy in High-Risk Breast Cancer
At the 2017 ASCO Annual Meeting, results were presented from the phase II I-SPY 2 trial investigating pembrolizumab (Keytruda) in combination with standard therapy (paclitaxel followed by doxorubicin and cyclophosphamide) as a neoadjuvant treatment for patients with locally advanced triple-negative ...
ASCO 2017: Ibrutinib Plus Cellular Therapy CTL119 May Lead to Complete Remissions in CLL
Combining the kinase inhibitor ibrutinib (Imbruvica) with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman School of Medicine at the University...
ASCO Congratulates NIH Director Francis Collins on Remaining in Critical Leadership Position
ASCO President Bruce E. Johnson, MD, FASCO, released the following statement today: “ASCO congratulates Francis S. Collins, MD, PhD, on the announcement of his continued service as the Director of the National Institutes of Health (NIH). A renowned researcher and skilled administrator, Dr....
ASCO 2017: Implementing Cost Transparency in Oncology
Being transparent about the cost of cancer treatments with patients has been increasingly recommended to help minimize financial harm and improve care, but what's preventing or derailing those conversations is less understood. New findings from Penn Medicine that identified several barriers and key ...
ASCO 2017: Many Emergency Department Visits Among Patients With Cancer Appear Preventable
Among patients with cancer, as many as 53% of emergency department visits that do not require admission could be avoided with better symptom management and greater availability of outpatient care tailored to their needs, according to a new study from Fred Hutchinson Cancer...
Daniel Heng, MD, MPH, and Sumanta K. Pal, MD, on Renal Cell Carcinoma: Expert Perspectives
Daniel Heng, MD, MPH, of the Tom Baker Cancer Centre and the University of Calgary, and Sumanta K. Pal, MD, of the City of Hope, discuss key findings presented at ASCO: adjuvant pazopanib vs placebo after nephrectomy in patients with locally advanced disease (the PROTECT Trial), and adjuvant...
Bernard J. Escudier, MD, and Sumanta K. Pal, MD, on RCC: Trial Results on Sunitinib
Bernard J. Escudier, MD, of Gustave Roussy Cancer Campus, and Sumanta K. Pal, MD, of City of Hope, discuss phase III study findings on adjuvant sunitinib used to treat high-risk renal cell carcinoma, which validate the 16-gene Recurrence Score in patients with stage III disease. (Abstract 4508)
Tanya B. Dorff, MD, and Sumanta K. Pal, MD, on Prostate Cancer: Expert Perspectives on STAMPEDE and a Phase IV Trial
Tanya B. Dorff, MD, of the USC Norris Comprehensive Cancer Center, and Sumanta K. Pal, MD, of the City of Hope, discuss two key presentations on prostate cancer: findings on adding abiraterone for men with high-risk prostate cancer starting long-term androgen-deprivation therapy, and an...
Neeraj Agarwal, MD, and Sumanta K. Pal, MD, on Prostate Cancer: Expert Perspectives on the LATITUDE Trial
Neeraj Agarwal, MD, of Huntsman Cancer Institute, and Sumanta K. Pal, MD, of the City of Hope, examine the study findings on androgen-deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. (Abstract LBA3)
Toni K. Choueiri, MD, and Sumanta K. Pal, MD, on Top Kidney Cancer Abstracts: Expert Perspectives
Sumanta K. Pal, MD, of City of Hope, and Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, exchange views on the key papers in renal cell carcinoma presented at ASCO’s 2017 nonprostate GU oral abstract session. (Abstracts 4504, 4505, 4506, 4507, 4508)
ASCO 2017: Early Research Suggests First Immunotherapy for Mesothelioma on the Horizon
Malignant pleural mesothelioma is a rare cancer, but its incidence has been rising. This cancer is usually associated with asbestos exposure, and patients have a median life expectancy of only 13 to 15 months. All patients relapse despite initial chemotherapy, more than 50% of them within 6 months...
ASCO 2017: BCMA-Specific CAR T-Cell Therapy Sends Relapsed/Refractory Multiple Myeloma Into Lasting Remission in an Early Trial
In an early clinical trial, 33 out of 35 (94%) patients had clinical remission of multiple myeloma upon receiving immunotherapy with chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein, or BCMA. Most patients had only mild side effects. The study was presented by Fan et al...
